Research Site
Vienna, Austria
NCT Number: NCT00516204
A screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus coronary heart disease) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <70mg/dl for such patients with very high risk) are screened. The doctors therapy decisions after the screening will be documented and 8-10 weeks later the lipid profile of each patient will be evaluated again. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Vienna, Austria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: After 4 weeks
Cholesterol levels from high risk patients after 4 weeks of cholesterol-lowering drug therapy under target values
AstraZeneca
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02341664
Angina, Angina Pectoris
Little Rock, Arkansas, United States
View Trial DetailsNCT01647438
Behavior, Body Weight
Chicago, Illinois, United States
View Trial DetailsNCT00079638
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT04181996
Arterial Occlusive Diseases, Arteriosclerosis
Edmonton, Alberta, Canada
View Trial Details